key: cord-0698611-8kn5s11p
authors: Shah, Melisa M; Salvatore, Phillip P; Ford, Laura; Kamitani, Emiko; Whaley, Melissa J; Kaitlin, Mitchell; Currie, Dustin W; Morgan, Clint N; Segaloff, Hannah E; Lecher, Shirley; Somers, Tarah; Van Dyke, Miriam E; Bigouette, John Paul; Delaney, Augustina; DaSilva, Juliana; O’Hegarty, Michelle; Boyle-Estheimer, Lauren; Abdirizak, Fatima; Karpathy, Sandor E; Meece, Jennifer; Ivanic, Lynn; Goffard, Kimberly; Gieryn, Doug; Sterkel, Alana; Bateman, Allen; Kahrs, Juliana; Langolf, Kimberly; Zochert, Tara; Knight, Nancy W; Hsu, Christopher H; Kirking, Hannah L; Tate, Jacqueline E
title: Performance of Repeat BinaxNOW SARS-CoV-2 Antigen Testing in a Community Setting, Wisconsin, November-December 2020
date: 2021-04-28
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab309
sha: c11c1dccf7744188313683c283b619c90cddffc4
doc_id: 698611
cord_uid: 8kn5s11p

Repeating the BinaxNOW antigen test for SARS-CoV-2 by two groups of readers within 30 minutes resulted in high concordance (98.9%) in 2,110 encounters. BinaxNOW test sensitivity was 77.2% (258/334) compared to real-time reverse transcription-polymerase chain reaction. Same day antigen testing did not significantly improve test sensitivity while specificity remained high.

M a n u s c r i p t 3 

Strategies to curb the current coronavirus disease 19 (COVID-19) pandemic are increasingly reliant on antigen-based diagnostics because of low cost, availability, and rapid turn-around. Abbott's BinaxNOW COVID-19 Ag Card (here on referred to as BinaxNOW) is a lateral flow antigen test resulting in 15 minutes and was initially approved for use in symptomatic individuals [1] . Recent reports suggest lower sensitivity compared to real-time reverse transcription-polymerase chain reaction (RT-PCR) among asymptomatic individuals [2] [3] [4] [5] . The ideal frequency of serial rapid tests and the role of confirmatory rapid testing at the same encounter is not well-described. To evaluate repeat antigen testing and test performance, this investigation embedded repeat BinaxNOW testing and simultaneous RT-PCR confirmation at a testing site where antigen tests were freely available to the public regardless of symptoms or exposures [6] . Concordance of repeat BinaxNOW testing as well as test performance in a community setting with high prevalence of SARS-CoV-2, the virus that causes COVID-19, is described.

Participants were recruited from registrants at a community SARS-CoV-2 testing site in Oshkosh, Wisconsin, during an ongoing mass surge testing campaign. BinaxNOW antigen testing in asymptomatic individuals, and one explanation is that this group may be in the early infectious period or recovery period when viral load is lower [5, 11, 12] .

There are several limitations to this investigation. Notes:

US Department of Health and Human Services, Food and Drug Administration

BinaxNOW COVID-19 Ag Card

Antigen Card test relative to the SARS-CoV-2 real-time reverse transcriptase polymerase chain reaction assay among symptomatic and asymptomatic healthcare employees

Performance Characteristics of BinaxNOW COVID-19 Antigen Card for Screening Asymptomatic Individuals in a University Setting

Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites-Pima County

Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing site in San Francisco

UW-Madison offers surge testing to community amid rise in cases

TaqPath™ COVID-19 Combo Kit. Food and Drug Administration

MD: US Department of Health and Human Services, Food and Drug Administration

Council of State and Territorial Epidemiologists (CSTE) Interim Position Statement: Update to COVID-19 Case Definition

COVID-19): interim guidance for antigen testing for SARS-CoV-2

Letter to Health Care Providers. Potential for False Positive Results with Antigen Tests

Analytical Sensitivity of the Abbott BinaxNOW COVID-19 Ag CARD

Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients

A c c e p t e d M a n u s c r i p t Cycle threshold values are for the N gene (one of the three targets) for all specimens positive by RT-PCR. c There were two indeterminate results from the initial BinaxNOW test and two indeterminate results from the repeated BinaxNOW test. All four were from separate enrollees, and the paired rapid test was negative except for one which had a threshold cycle of 30.7. Among discordant participants, 18/24 were symptomatic including all 14 participants with a negative to positive result. d CI = Confidence Interval e The repeated BinaxNOW test row defines positive as having either an initial or repeat BinaxNOW test that was positive at the same encounter. f Defined as ≥ 1 current symptom from 15 symptom criteria for the COVID-19 case definition from the Council of State and Territorial Epidemiologists (CSTE). https://www.cste.org/news/520707/CSTE-Interim-Position-Statement-Update-to-COVID-19-Case-Definition.htm